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Background: The T-lymphocyte cell-surface molecule,
CD2, was the first heterophilic cell-adhesion molecule
to be discovered and has become an important paradigm
for understanding the structural basis of cell adhesion.
Interaction of CD2 with its ligands, CD58 (in humans)
and CD48 (in mice and rats), contributes to antigen
recognition by T cells. CD2, CD48 and CD58 are closely
related members of the immunoglobulin superfamily and
their extracellular regions are predicted to have very simi-
lar structures. The three-dimensional crystal structure of
this region of CD2 has been determined, revealing two
immunoglobulin domains with the ligand-binding site
situated on an exposed sheet in the membrane-distal
domain. This GFCC'C" P sheet is also involved in a
homophilic 'head-to-head' interaction in the CD2 crystal
lattice, which has been proposed to be a model for the
interactions of CD2 with its ligands.
Results: We show that the CD2-binding site on rat
CD48 lies on the equivalent 3-sheet of its membrane-
distal immunoglobulin domain. By making complemen-
tary mutations, we have shown that two charged residues
in the CD48 ligand-binding site interact directly with
two oppositely charged residues in CD2's ligand-binding
site. These results indicate that the amino-terminal
immunoglobulin domains of CD2 and CD48 bind each
other in the same orientation as the CD2-CD2 crystal
lattice interaction, strongly supporting the suggestion that
CD2 interacts head-to-head with its ligand. Modelling
CD48 onto the CD2 structure reveals that the
CD2-CD48 complex spans approximately the same
distance (134 A) as predicted for the complex between
the T-cell receptor and the peptide-bound major
histocompatibility complex (MHC) molecule.
Conclusions: Our results, together with recent structural
studies of CD2, provide the first indication of the specific
topology of a cell-adhesion molecule complex. The
similar dimensions predicted for the CD2-CD48 com-
plex and the complex between the T-cell receptor and
the peptide-bound MHC molecule suggest that one of
the functions of CD2 may be to position the plasma
membranes of the T cell and the antigen-presenting (or
target) cell at the optimal distance for the low-affinity
interaction between the T-cell receptor and the peptide-
bound MHC molecule.
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Background
The diverse specificity of the adaptive immune response
resides in two large repertoires of antigen receptors,
namely antibodies and T-cell receptors (TCRs), produced
by B and T lymphocytes, respectively. Although there are
many similarities between TCRs and antibodies, there
are several important differences. Whereas antibodies are
secreted into solution and bind to intact antigen, TCRs
remain on the cell surface and always bind to a complex
of processed peptide antigen and major histocompatibility
complex (MHC) class I or class II molecules on the
surface of antigen-presenting or target cells [1].
The dimensions of the MHC class I [2] and II [3] mol-
ecules and the predicted dimensions of the TCR [1,4-6]
are small (around 75-90 A in length) compared with the
size of abundant leukocyte cell-surface glycoproteins such
as CD43 and CD45, which range in length from 280
to 550 A [7,8]. Expression of CD43 inhibits T-cell inter-
actions mediated by even relatively large cell-adhesion
molecules such as the integrins [9,10], suggesting that
CD43, CD45 and similar molecules act as physical con-
straints on the interaction of the TCR with peptide-
bound MHC molecules. Another important difference
between TCRs and antibodies is their affinity for anti-
gen, which is several orders of magnitude lower for
TCR-MHC interactions (Kd = 1-5 x 10 - 5 M [11,12])
than for typical antibody-antigen interactions
(Kd = 10-11 to 10-7 M [13]).
These considerations suggest that antigen recognition by
T lymphocytes requires assistance from cell-adhesion
molecules to initiate and maintain contact with antigen-
presenting or target cells [11,14]. CD2 was one of the
first cell-adhesion molecules to be implicated in T-cell
antigen recognition (see [15] for review) and the major
ligands identified for CD2 are CD58 (in humans) [16,17]
and CD48 (in rodents) [18,19], both of which are struc-
turally related to CD2 [20]. The crystal structures of the
entire extracellular regions of both rat [21] and human
[22] CD2 have been solved, revealing that CD2 contains
two immunoglobulin domains, a membrane-distal V-set
domain and a membrane-proximal C2-set domain. V-set
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and Cl-set immunoglobulin domains are similar to
antibody variable and constant domains, respectively,
whereas C2-set domains have features of both [23]. Se-
quence comparisons suggest that CD48 and CD58 have
very similar structures to CD2 [20-22].
The CD58-binding site of human CD2 is in an exposed
position on the so-called GFCC'C" 13-sheet of the mem-
brane-distal V-set immunoglobulin domain [24-26], and
the CD48-binding site on rat CD2 is in essentially the
same position (E.A.D., P.A.V. and S.J.D., unpublished
observations). There is evidence that CD2 binds to the
equivalent region of CD58 [27,28], but the position of
the rat CD2-binding site on CD48 is not known and
there, is no information on the topology of CD2 interac-
tions. When the crystal structures of CD2 from rats [21]
and then humans [22] were solved, CD2 was found to be
involved in a homotypic, 'head-to-head' interaction in
the crystal lattice, making contact through the GFCC'C"
sheet of its V-set domain.
Interestingly, the chromosomal organization and
sequence similarity of the CD2, CD48, and CD58 genes
is consistent with the hypothesis that all three cell-adhe-
sion molecules evolved from a common ancestral mol-
ecule by gene duplication [29-32]. Although there is no
evidence that CD2 interacts homotypically under physi-
ological conditions ([33]; P.A.V and S.J.D., unpublished
observations), it is possible that the head-to-head interac-
tion observed in the crystal lattice [21,22] resembles an
earlier homotypic interaction of the ancestral adhesion
molecule. The head-to-head topology might be con-
served in the heterotypic CD2-CD58 and CD2-CD48
interactions, a possibility that is consistent with the avail-
able data on the CD2 and CD58 ligand-binding sites.
For these reasons, the CD2 head-to-head interaction has
been proposed as a possible paradigm for interactions
between adhesion molecules of this type [21,22].
An alternative arrangement of interacting V-set
immunoglobulin domains was first observed between
variable domains of antibody heavy (VH) and light (VL)
chains [34]. More recently this arrangement was
observed between the V-set domains of the CD8 cxt
homodimer [35], and it is also likely to occur between
the variable V-set immunoglobulin domains of the TCR
[4,5]. In this arrangement, the GFCC'C" sheets of V-set
domains make contact through a complex, three-layer
packing interaction [34]. These GFCC'C" sheets have
large -bulges in their G and C' strands, which bear
residues with side chains that form a third layer between
the two sheets [34]. This type of three-layer packing
interaction has been proposed for CD2 interactions [36]
and is consistent with the available data on the CD2 and
CD58 ligand-binding sites.
In this study, we aimed to identify the precise position of
the CD2-binding site on rat CD48 and to determine the
orientation of the interacting binding sites. Deter-
mination of the binding orientation provides a rigorous
test for the hypothesis that CD2 interacts with its ligands
in a head-to-head interaction, and can eliminate alterna-
tive arrangements such as the three-layer packing inter-
action. We show that CD2 binds to the GFCC'C" face
of the V-set domain of CD48, and we use a complemen-
tary mutagenesis strategy to determine the orientation of
the interacting CD2 and CD48 binding sites. Our results
strongly support a head-to-head interaction and rule out
a three-layer packing interaction.
Results and discussion
Mutagenesis strategy
Previous studies have shown that the ligand-binding sites
on CD2 from rats [19] and humans [24-26], and human
CD58 [27], all lie within the V-set domains of these pro-
teins. In the present study, mutations were therefore
made in the amino-terminal V-set immunoglobulin
domain of CD48. To facilitate the selection of mutations
and interpretation of the mutational data, the sequence of
domain 1 of rat CD48 was aligned with the equivalent
regions of CD2 (Fig. 1), the structure of which is known
and is likely to be very similar to that of CD48
[21,22,37,38]. The rat CD48 sequence aligns particularly
well with the A, B, C, C', E, and F 3-strands of CD2
(Fig. 1). The C"-strand assignment for CD48 was based
on the position of the phenylalanine (F) at residue 54
(Fig. 1), because a F is found in this position in all known
CD2 sequences [39] as well as in CD48 and CD58
sequences [20,31]. The loops between the 3 strands are
mostly poorly conserved (Fig. 1); this is typical for
immunoglobulin superfamily proteins. The inter-domain
linker region leading from the G strand of domain 1 to
the A strand of domain 2 is, however, highly conserved
in CD48 (Fig. 1).
A widely used strategy for identifying binding sites on
proteins is alanine-scanning mutagenesis, in which
amino-acid residues are systematically mutated to alanine
[40]. In a recent analysis of growth hormone binding to
its receptor [41], however, alanine-scanning mutagenesis
identified only about one quarter of the residues that had
been shown previously to be buried in the crystal struc-
ture of the hormone-receptor complex [42]. These
results indicate that alanine-scanning mutagenesis identi-
fies only the 'functional' binding site, comprising the
side chains that contribute to the binding energy, and
that this site is likely to lie within a larger 'structural'
binding site, which is defined as the surface region that is
buried upon ligand binding [41]. As the aim of the pre-
sent study was to delineate the structural binding site, it
was important to ensure that the mutations of CD48
identified the full extent of its CD2-binding site. We
therefore made drastic changes to residues that, on the
basis of the sequence alignment, are predicted to lie on
the surface. All neutral or polar residues were mutated to
charged residues, and all charged residues were mutated
to change the charge. This approach has the additional
advantage that, if a buried residue is mistakenly mutated
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Fig. 1. Alignment of rat CD48 with the rat
and human CD2 sequences. Rat and
human CD2 were aligned by the super-
position of their structures 122]. Rat
CD48 was aligned against the CD2 align-
ment using the program AMPS [66], with
20-fold-higher penalties for gaps and
insertions within the 3-strands than in
loops. Minor adjustments to the align-
ment were then made manually. The
positions of the -strands in the CD2
structures are indicated by the bars
above the sequences. Residues con-
served in CD48 and at least one of rat or
human CD2 are boxed; triangles show
residues that are buried in the rat CD2
structure; residues that make contact in
the human and rat CD2 crystal lattice
interactions are indicated by asterisks.
The results of the present study suggest
that the CD48 residues shaded in blue
contribute to the CD2-binding site. The
numbering above and below the aligned
sequences refers to the (mature) rat CD48
and rat CD2 proteins, respectively.
because of an incorrect alignment, the structure will be
unlikely to fold at all. A protein that does not fold is
unlikely to be expressed and, even if it is expressed, the
lack of folding is easily detected by a loss of binding to
monoclonal antibodies.
Analysis of CD48 mutants
The analysis of the CD48 mutants was performed using
the BIAcore biosensor [43], with methods that have
been described previously [44]. In a BIAcore experi-
ment, one ligand is immobilized on a dextran matrix
within a small flow-cell, and the other is injected
through the flow-cell. If the soluble ligand binds the
immobilized one, the protein concentration within the
matrix increases, altering the refractive index; the change
in refractive index is measured in response units. The
technique's sensitivity to protein concentration means
that when high concentrations of protein are injected, a
background signal is observed.
To facilitate analysis, mutations were introduced into a
soluble, chimeric CD48 protein (srCD48-CD4), com-
prising domains 1 and 2 of rat CD48 fused to domains 3
and 4 of rat CD4 [45], and the mutants were expressed
by transient transfection of COS-7 cells. Tissue culture
supernatant containing the expressed mutant
srCD48-CD4 protein was injected over a sensor surface
to which the anti-CD4 monoclonal antibody OX68 had
been covalently immobilized (Fig. 2a). If the mutant
srCD48-CD4 chimeras were expressed, they bound to
OX68 (blue bar, Fig. 2b-f) and remained bound after the
tissue culture supernatant injection was completed, as
indicated by the elevated baseline response following the
injection (Fig. 2b-f). In order to test for binding of rat
CD2, a chimeric CD2 protein comprising glutathione-
S-transferase (GST) fused to the amino terminus of the
V-set domain (dl) of rat CD2 (CD2dl-GST; Fig. 2a)
[37], was injected over the bound sCD48-CD4 mutants.
The advantage of using the CD2dl-GST chimera is that
the GST domain dimerizes, thus enhancing the avidity of
the weak CD2-CD48 interaction [44]. In a typical
experiment, CD2 binding was detected by injecting the
control protein, bovine serum albumin (BSA), and
CD2dl-GST both before and after the binding of the
srCD48-CD4 mutant to the sensor surface (orange and
red bars, Fig. 2b-f). Small, non-specific responses are seen
in all the traces in response to the BSA and CD2dl-GST
injections because of their relatively high protein concen-
tration (0.5 mg ml-] and 0.1 mg ml-1, respectively).
Normal binding of CD2 to the wild-type srCD48-CD4
chimera is illustrated in Figure 2b. When injected after
binding of srCD48-CD4 to the surface, the BSA
response is unchanged but the CD2dl-GST response is
dramatically increased, indicating binding (Fig. 2b).
A total of 26 mutations of CD48 in 22 different positions
were analyzed for their effect on CD2 binding and they
could be divided into three groups (Table 1 and Fig. 3).
In the first group, illustrated by the mutant Y85D (repre-
sented by the single-letter amino-acid code, numbered as
in mature CD48), the binding to CD2 was indistinguish-
able from wild-type CD48 (Fig. 2c). Fourteen mutants
in nine different positions had this phenotype (Fig. 3;
Table 1). In the second group, binding to CD2dl-GST
was decreased, but was still clearly detectable. Only two
mutants, H36E and R31E, had this phenotype (Fig.
2d,e; Table 1). A monomeric form of rat CD2 was used
to measure the affinity of CD2 for these mutants, as
described previously [44]. The affinities were too low to
measure precisely, however, and could only be shown to
be reduced at least five-fold compared with that of wild-
type CD48 (data not shown). The third group of
mutants showed no binding to CD2dl-GST, as illus-
trated by the mutant E44K (Fig. 2f). There were ten
mutants in this group, affecting seven different positions
(Table 1). In summary, a total of twelve mutations of
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Fig. 2. Analysis of CD2 binding to CD48
mutants. (a) Summary of the experi-
mental approach. (b-f) Tissue culture
supernatant containing the indicated
srCD48-CD4 mutant (represented by
the single-letter amino-acid code) was
injected for 12 min (blue bar) into a
flow-cell in which the anti-CD4 mono-
clonal antibody OX68 had been immo-
bilized onto the sensor surface. An
initial rapid increase in the response
(which results from the different re-
fractive index of the tissue culture
supernatant) is followed by a slower
increase as the srCD48-CD4 binds to
the sensor surface via the monoclonal
antibody. At the end of the injection, as
the supernatant is washed out, the
response drops rapidly to a new higher
baseline, which represents bound
srCD48-CD4. Bovine serum albumin
(BSA, 0.5 mg ml - l ) (orange bars) and
srCD2dl-GST (0.1 mg ml- 1) (red bars)
were injected for 20 s and 60 s, respec-
tively, before and after the srCD48-CD4
was bound to the sensor surface. An
increase in the response to the injection
of srCD2dl-GST reflects binding to that
particular srCD48-CD4 mutant (b-e),
whereas no increase (f) indicates that
CD2 does not bind that mutant.
nine different positions abolished or drastically 'decreased
CD2 binding (Table 1; Fig. 3).
When the mutations are plotted onto a model of domain
1 of rat CD48, it is clear that all the mutations that affect
binding to CD2 lie in a contiguous patch on the
GFCC'C" face (Fig. 3). The binding site is well-circum-
scribed, in that there are mutations surrounding it that
have no effect on binding to CD2. These included muta-
tions predicted to be in the B-C (K23E, S28E), C-C'
(T38R, N39D), C'-C" (F46D, K50E and T52R), C"-D
(K59E), and F-G (H90D, E91K) loops, and mutations
predicted to lie in the bottom half of the F strand (Y85D)
or the bottom two-thirds of the G strand (Q95R,
ElO1R) (Fig. 3). The binding site delineated by these
mutants is extensive, stretching across five 3-strands from
side to side (G, F, C, C', and C"), and over six residues in
strand C from top to bottom (Fig. 3).
In order to check that the mutant proteins were folded
correctly, they were analyzed for binding to the anti-rat-
CD48 monoclonal antibodies OX45 and OX46 [46],
which block the binding of rat CD2 to CD48 ([19];
P.A.V. and P.N.M., unpublished observations). All the
mutants that showed decreased binding to CD2 bound to
both OX45 and OX46, with the exception of R31E
which bound neither antibody. The mutations E91K,
H90D, and F46D also abrogate binding to the antibodies,
but they do not disrupt binding to CD2 (Table 1); all of
these mutants are predicted to lie towards the top end of
domain 1 in the F-G and C'-C" loops (Fig. 3). Taken
together, these results suggest that the monoclonal anti-
body-binding and CD2-binding sites on CD48 overlap
in the region of R31. Despite the absence of binding to
antibody, the R31E mutant is likely to be correctly
folded because it shows some binding to CD2 (Fig. 2e),
and this binding is dramatically improved by a single,
complementary mutation in rat CD2 (see below).
Comparison of the CD48 binding site with the CD2 ligand-
binding site and CD2-CD2 crystal lattice contact region
Homodimers of rat and human CD2 observed in the
crystal lattices make contact over an extensive region on
the GFCC'C" -sheet of domain 1 [21,22]. The inter-
action involves side chains of residues in the G, F C, C'
and C" strands and the protein backbone in the C-C'
and F-G loops (Fig. 1) [21,22]. The binding site on
CD48 delineated by our mutagenesis results corresponds
very well with this contact region (Figs 1 and 3), and
mutagenesis of rat CD2 has delineated essentially the
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leucine [25], however, and these changes may have been
too conservative to disrupt binding if F54 makes only a
small contribution to the binding energy.
Identification of complementary CD2 and CD48 mutations
Our data, taken together with mutagenesis data for
human and rat CD2, indicate that CD2 and CD48 inter-
act through equivalent regions of the GFCC'C" 3-sheet
of their V-set domains. But these data give no indication
of the orientation of the interacting binding sites, infor-
mation that is critical for determining the overall topol-
ogy and dimensions of the CD2-CD48 complex. One
way to identify the precise orientation of two interacting
proteins is to solve the crystal structure of the complex
of the two molecules. This approach is technically diffi-
cult, however, and has been successful in only a small
number of cases, in which the interactions are of high
affinity; these include the complex between growth hor-
mone and its receptor [42] and several enzyme-inhibitor
and antibody-antigen complexes [47].
The approach we used to determine the orientation of
interacting binding sites was to identify mutations of
CD2 that complement mutations of CD48 by restoring
binding to CD48 mutants that bind only very poorly to
wild-type CD2. Mutant residues that complement each
other are likely to be in contact with one another. If two
pairs of interacting residues can be found, the relative
Fig. 3. Model of rat CD48 depicting the mutations which disrupt
CD2 binding. The protein backbone of the V-set domain of rat
CD48 was modelled on the rat CD2 structure using the align-
ment shown in Fig. 1 (see Materials and methods). The predicted
positions of the mutants which abrogated (red circles) or had no
effect on CD2 binding (blue circles) are shown. The view shown
is approximately perpendicular to the GFCC'C" -sheet. This
figure was drawn using MOLSCRIPT 167].
same area as the CD48-binding site (E.A.D., P.A.V., and
S.J.D., unpublished observations). It should be empha-
sized that our finding of no effect of mutations in the
C-C' and F-G loops (Fig. 3) does not preclude a contri-
bution to CD2 binding by the protein backbone in these
loops, and so remains consistent with the CD2-CD2
homodimer interactions seen in the crystal lattice.
Mutagenesis studies of human CD2 [24-26] have also
shown that the CD58-binding site lies on the GFCC'C"
[3-sheet of domain 1 [22,38], but there are some differ-
ences between the human CD2 ligand-binding site iden-
tified in these studies and the CD48 ligand-binding site
identified in the present study. First, mutations of residues
in the C-C' and F-G loops of human CD2 were
reported to disrupt binding to CD58 [24-26]. Second,
mutations of the C"-strand residue F54 in human CD2
[25,26] did not affect binding to CD58, whereas this
conserved residue contributes to the ligand-binding site
of rat CD48 (Fig. 3) and rat CD2 (E.A.D., P.A.V., and
S.J.D., unpublished observations) and is a contact residue
in homodimers of human and rat CD2 (Fig. 1). The
mutation of F54 in human CD2 was to alanine [26] or
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residue on CD2 with which it makes contact. In order to
screen for such complementary mutants, CD48 mutants
that bind poorly to CD2 were tested for binding to a
panel of CD2 mutants that do not bind wild-type CD48
(E.A.D. P.A.V. and SJ.D., unpublished observations).
A typical experiment is shown in Figure 4. When four
CD2 mutants (E29R, R87E, E41R, and K43E) were
injected over immobilized wild-type srCD48-CD4 (Fig.
4a), the response was the same as when no
srCD48-CD4 was immobilized (Fig. 4a, inset), indicat-
ing that these CD2 mutants did not bind wild-type
CD48. When the srCD48-CD4 mutant E44K was
immobilized, however, the CD2 mutant K43E was able
to bind (Fig. 4b). As the CD48 mutant E44K does not
bind wild-type CD2 (Fig. 2f), this result indicates that
the mutations E44K in CD48 and K43E in CD2 com-
plement each other. Similarly, the CD2 mutant E41R
was able to bind very well to the CD48 mutant R31E
(Fig. 4d), whereas it did not bind wild-type CD48 (Fig.
4a), and the CD48 mutant R31E binds poorly to wild-
type CD2 (Fig. 2e). Two additional CD2 mutants with
charge changes (E29R and R87E; Fig. 4a-e) and two
additional CD48 mutants with charge changes (E93R
and K41E; Fig. 4c,e) are included in these experiments
as controls. In all, 108 combinations of CD2 and CD48
mutants were screened for binding, but no other pairs of
mutants were found to complement each other (Table
2). These results indicate that the binding observed
between these two pairs of complementary mutations is
unlikely to be the result of non-specific charge changes
on the two binding surfaces.
Fig. 4. Identification of CD2 mutants that complement CD48
mutants. The approach used is the same as in Fig. 2a. Wild-type
(a) or mutant (b-e) srCD48-CD4 was bound to the sensor sur- simplest explanation for our results is that when rat
face by injecting tissue culture supernatant containing the indi- CD2 binds CD48, the binding sites are orientated so that
cated srCD48-CD4 mutant over the immobilized anti-CD4 the residues E44 and R31 on CD48 are in close contact
monoclonal antibody for 12 min (blue bar). Different
srCD2dl-GST mutants (all at 0.1 mg ml-1) were injected for
1 min over the bound srCD48-CD4 mutants. As a negative con-
trol, the srCD2dl-GST mutants were also injected over the anti-
CD4 monoclonal antibody before any srCD48-CD4 was bound
(inset in (a)). None of the CD2 mutants bound wild-type CD48,
or the E93R or K41E mutants (compare with inset). But
CD2-K43E bound CD48-E44K, and CD2-E41R bound
CD48-R31 E. Note the different order of CD2 injections in (d).
orientation of the interacting binding sites can be deter-
mined. A related approach was used by Davis and co-
workers [48] to identify residues involved in contacts
between TCR and peptide.
The ligand-binding surface of rat CD2 has large numbers
of charged residues [21], as does the predicted ligand-
binding surface of CD48 (Figs 1 and 3). There are 13 and
15 charged residues on and around the GFCC'C" sur-
faces of rat CD2 and CD48, respectively (Fig. 1), so it
seemed likely that at least some of the charged residues of
CD48 interact with oppositely charged residues of CD2.
We reasoned that the disruption of binding that results
from mutation of a charged residue on CD48 might be
reversed if a complementary change were made to the
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with the CD2 residues K43 and E41, respectively.
Changing the charges of these residues could disrupt
binding either by removing energetically important
bonds, such as salt bridges, or by introducing repulsive
forces between similarly charged residues on the ligand-
binding site (or by a combination of the two). It follows
that our results do not necessarily imply that the inter-
action of the CD48 residues R31 and/or E44 with CD2
residues E41 and/or K44 contribute significantly to the
binding energy of the CD48-CD2 interaction. Indeed,
our finding that the drastic CD48 mutation R31E does
not completely abolish binding (Fig. 2) suggests that R31
contributes little to the binding energy. Further evidence
that these residues are not crucial for CD2 interactions is
that neither of the rat CD2 residues E41 or K43 is con-
served in humans (Fig. 1). Similarly, human CD58 and
CD48 have Glu and Gln in place of the rat CD48 Arg at
residue 31 (not shown). It should be emphasized that
these sequence differences do not preclude close contact
between these residues in the human CD2-CD58 or
CD2-CD48 interactions.
Fig. 5. Alternative models for the CD2-CD48 interaction. The Ca
backbone traces of the V-set domains of CD2 (yellow) and CD48(white) are shown binding in (a) a head-to-head interaction,
which is supported by the results of the complementary muta-
genesis, and (b) a three-layer packing interaction, which cannot
account for the data. The residues that were shown to interact by
the complementary mutagenesis are shown in blue (positively
charged) and red (negatively charged). The view on the left is
parallel to the interacting GFCC'C" sheets, with the membrane-
distal ends of CD2 and CD48 on the left- and right-hand sides,
respectively, whereas the view on the right is perpendicular to
the interacting GFCC'C" sheets, with the membrane-distal ends
of CD2 and CD48 on the right and top, respectively. In this view,
the BED sheets have been left out for clarity.
The orientation of the CD2-CD48 interaction
The two pairs of complementary mutants can be used to
determine the relative orientation of the interacting V-set
domains of CD2 and CD48. The reliability of this pre-
diction will depend on whether CD48 residues R31 and
E44 have been accurately positioned on the GFCC'C"
sheet of the CD48 model by the alignment. The align-
ment of residue R31 of CD48 with E29 of CD2 is
almost certainly correct, as it is based on the alignment of
the buried C-strand W residue of CD2 and CD48
(CD48 W34, Fig. 1), and this is one of the most highly
conserved residues in immunoglobulin domains [23].
The alignment of E44 of CD48 with E41 in the C'
strand of CD2 is also very likely to be correct for the fol-
lowing reasons: firstly, five out of six residues in this
region are conserved between CD48 and either human
or rat CD2 (Fig. 1); secondly, the unusual (for a [-sheet)
pattern of consecutive buried hydrophobic residues in
the C' strand (Fig. 1) is conserved in the structures of
most V-set domains (reviewed in [5]), including human
and rat CD2 [21,22,37,38] and human CD4 [49,50].
Taken together, these considerations support the C'-
strand alignment shown in Figure 1 and the hypothesis
that the CD48 residue E44 is structurally equivalent to
the CD2 residue E41.
Fixing the CD48 residues R31 and E44 on the
GFCC'C" sheet enabled us to determine which orien-
tation of the CD2- and CD48-binding surfaces is con-
sistent with the mutagenesis results. Two types of
interaction between GFCC'C" 13-sheets of V-set do-
mains have been described previously (see Background).
The best-characterized of these is the three-layer packing
interaction seen in antibodies and the CD8 o homod-
imers [34,35]. When the structure of domain 1 of CD2
was reported to be a V-set domain, and it was clear that
the ligand-binding site was on the GFCC'C" sheet [37],
it was suggested that the interaction of CD2 with its lig-
and might be similar to the interaction of VH and VL
domains in antibodies [36]. As the immunoglobulin
domains are orientated in approximately the same direc-
tion in the three-layer packing interaction, this would
require a substantial bend after the V-set domains to
direct the carboxyl termini of the interacting proteins
towards apposing cell membranes. Most of this bend
would have to be in the linker region between the rigid
V-set and C2-set immunoglobulin domains. Such a bend
was not observed when the crystal structures of the entire
extracellular region of CD2 from rat [21] and human
[22] were obtained, but as these studies showed clear evi-
dence for flexibility in the linker region, a three-layer
packing interaction could not be excluded.
Recently, an alternative type of V-set domain interaction
has been observed between homodimers that are present
in the crystals of both rat and human CD2 [21,22]. In
this head-to-head interaction, the GFCC'C" sheets are
more closely apposed and are rotated approximately 1100
relative to each other, compared with about 500 in the
three-layer packing interaction [21,22]. The head-to-head
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framework of the other V-set domain (white) in the
position equivalent to CD2 residues E41 and E29,
respectively. It is clear from the two views shown (Fig.
5a) that these residues would be in close proximity in a
head-to-head interaction between CD2 and CD48. As
the side chains of the interacting residues (E, K and R)
are large and have multiple rotamers, their precise posi-
tion cannot be predicted. Indeed, some variation is seen
in the CD2 head-to-head interaction [21,22]. Never-
theless, it is clear that the head-to-head orientation
brings the interacting residues into close proximity, pro-
viding strong evidence that CD2 and CD48 interact in
this orientation.
Fig. 6. Models of the CD2-CD48, TCR-peptide-MHC and
CD4-MHC complexes. The molecules shown are all Ca traces of
crystal structures of proteins. The CD2-CD48 complex is essen-
tially the same structure as the crystal homodimer of rat CD2 (yel-
low) with CD48 (white) modelled on one of the CD2 molecules
[211. The two pairs of interacting residues identified in the present
study are shown at the CD2-CD48 interface (coloured as in Fig.
5). The TCR (blue) is represented by the IgG Fab' fragment NEW
[51]. The MHC class II molecule (green) is HLA-DR1 with a
bound influenza virus peptide antigen (pink) [3,521. The TCR
model was docked on HLA-DR1 in an orientation that positions
the CDR3 hypervariable loops over the peptide, and the CDR1
and CDR2 hypervariable loops over the a helices [1,4-6,48]. The
CD4 model (orange) was constructed as described [53] from the
structures for human CD4 domains 1 and 2 and rat CD4 domains
3 and 4. Regions in CD4 [68,69] and HLA-DR1 [54,55] that are
believed to interact are shown in red. The distances spanned by
the proposed CD2-CD48, TCR-MHC, and CD4-MHC com-
plexes are 134 A, 135 A, and 125 A, respectively. The additional
amino-acid residues that lie in the carboxy-terminal stalk region
between the membrane-proximal immunoglobulin domains and
the transmembrane domains (CD2, 4 residues; CD4, 8 residues;
TCR a, -16 residues; TCR 3, -34 residues; MHC class II a, 9
residues; MHC class 11 3, 8 residues) or GPI anchor (CD48, -5
residues) are not included in these measurements because the
structures of these segments are not known.
interaction orientates the interacting proteins in opposite
directions, which is appropriate for interactions of cell-
adhesion molecules as they are directed from apposing
cell membranes. This interaction therefore provides a
plausible model for the interaction of CD2 with its
natural ligand [21].
We tested the hypothesis that CD2 interacts with CD48
in a head-to-head interaction by examining whether this
arrangement brings the putative interacting residues
close together. Figure 5a shows two views of the a-car-
bon backbone of interacting V-set domains in the rat
CD2 crystal homodimer. The CD2 residues K43 and
E41 are shown on one of the V-set domains (yellow) and
the CD48 residues E44 and R31 are shown on the
We also examined whether the three-layer packing
interaction was consistent with our results by super-
imposing CD2 and CD48 on the framework -strands
of the interacting VH and VL domains of an antibody
(Fig. 5b). It is clear that an orientation equivalent to a
classical three-layer packing interaction cannot position
the interacting residues near to each other, thus making
it very unlikely that CD2 interacts with CD48 in this
orientation.
Predicted dimensions of the CD2-CD48 complex
Sequence comparisons indicate that the C2-set domain
(domain 2) of CD48 is very similar to the C2-set domain
of CD2, and the linker region between the two domains
is particularly highly conserved (Fig. 1). It therefore
seems likely that the overall structure of the extracellular
region of CD48, including the relationship between the
V-set and C2-set domains, will be similar to the CD2
structure. It follows that the CD2-CD48 complex will
have a similar overall structure and similar dimensions to
the CD2-CD2 crystal lattice homodimer (Fig. 6).
Measurement of the dimensions of such a CD2-CD48
complex indicates that it will span a distance of approxi-
mately 134 A (Fig. 6). This distance is small when com-
pared with the dimensions of some of the most abundant
cell-surface glycoproteins, such as CD43 and CD45,
which range in length from 280 to 550 A. For compari-
son, we estimated the size of the complex between the
TCR and peptide-bound MHC. Alignment of the a
TCR's ot and P subunits with the many available anti-
body structures has led to the conclusion that the TCR is
likely to have a very similar structure to that of the Fab
fragment of an immunoglobulin [1,4-6]. We therefore
docked the Fab fragment of the NEW antibody onto the
MHC class II molecule HLA-DR1 in an orientation that
positions the Vot and VP CDR3 loops over the peptide
groove (Fig. 6) [3,51,52]. The entire TCR-MHC com-
plex spans 135 A, which is remarkably similar to the
distance predicted for the CD2-CD48 complex (Fig. 6).
Sufficient data are also available to allow estimation of the
dimensions of the CD4-MHC class II complex (see Fig.
6). The structure of the entire extracellular region of
CD4, as modelled from the structure of its amino- and
carboxy-terminal halves, is estimated to span approxi-
mately 120 A [53]. As the amino-terminal domain of
CD4 interacts with the membrane-proximal 32 domain
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of MHC class II molecules [54,55], the complex of CD4
and MHC class II will span approximately 125 A (Fig. 6),
which is slightly smaller than predicted for the
TCR-MHC complex. It should be noted that there is
some uncertainty as to the precise dimension of these
complexes, as the TCR and CD48 structures are models.
Furthermore, all these molecules have some additional
residues with undefined structure in their membrane-
proximal stalk regions (see Fig. 6 legend).
Possible role for CD2 in T-cell antigen recognition
Recent data have raised questions about the precise role
of cell-adhesion molecules such as CD2, CD4 and CD8
in antigen recognition by T cells. It is paradoxical that,
despite abundant evidence that blocking CD2, CD4,
and CD8 interactions with antibodies dramatically
inhibits antigen recognition (reviewed in [15,56]), T
cells that mature in mice born without one of these
cell-adhesion molecules are still capable of apparently
normal antigen recognition [57-59]. The differential-
avidity model of T-cell maturation [60], which is sup-
ported by a number of recent experiments (reviewed in
[60]), provides an explanation that is consistent with
these results. In this model, the selection of randomly
generated T-cell clones for maturation depends on them
forming the correct number of complexes between the
TCR and self-peptide-bound MHC molecules when
they engage antigen-presenting cells in the thymus.
Maturation in the absence of a particular adhesion
molecule that normally enhances the TCR-MHC
interaction would thus lead to the selection of a differ-
ent repertoire of T-cell clones, which have attained
the required number of TCR-MHC complexes
through possession of a TCR with a higher affinity for
self-peptide-bound MHC molecules.
Our results indicate that the dimensions of the
CD2-CD48 complex are probably very similar to those
of the TCR-MHC complex. We suggest that CD2
functions not only to bring the T-cell and antigen-pre-
senting-cell or target-cell membranes together, but more
specifically, to position them at a distance that maximizes
the chances of TCR-MHC interactions. The extremely
fast solution kinetics of the CD2-CD48 and CD2-CD58
interactions [44,61], and the fact that CD48 has (and
CD58 can have [62]) a highly mobile glycosyl-
phosphatidylinositol lipid anchor [20], suggests that CD2
complexes in the contact regions between the T cell and
the antigen-presenting cell are likely to be highly
dynamic, continuously forming and dissociating [63].
Such a dynamic adhesion molecule interaction could
facilitate antigen recognition by enabling the MHC mol-
ecules, only a fraction of which bear the correct peptide
antigen, to move more freely through the contact regions
between the T cell and the antigen-presenting cell in
order to be sampled rapidly by the TCR. This special-
ized role for CD2 in antigen recognition is consistent
with the available data on CD2 function and can be
specifically tested by, for example, manipulating the
dimensions of CD2 and its ligands.
Conclusions
This study provides the first experimental data that clearly
define the orientation of two interacting cell-adhesion
molecules, and indicates that the membrane-distal V-set
domains of CD2 and CD48 interact in a head-to-head
orientation, analogous to the CD2-CD2 homodimer
interaction observed in the CD2 crystal lattices. Our
results suggest that the rat CD2-CD48 interaction, and
presumably the human CD2-CD58 interaction, span a
distance very similar to that spanned by the TCR-MHC
complex (around 135 A). We propose that CD2 enhances
antigen recognition by T cells by positioning their plasma
membranes and those of antigen-presenting or target cells
at a distance that optimizes the low-affinity TCR-pep-
tide-MHC molecule interaction.
Materials and methods
Expression of CD48 mutants
DNA encoding a rat CD48 chimeric protein comprising the
extracellular portion of CD48 fused to domains 3 and 4 of rat
CD4 (srCD48-CD4) constructed as described previously [45],
was excised from pBluescript KS+ using XbaI and BamHI,
blunt-ended, and subcloned by blunt-ended ligation into the
XbaI site of the phagemid expression vector pEF-BOS [64].
The DNA sequence was confirmed by dideoxy sequencing.
All sequencing was performed using the Applied Biosystems
Model 373A DNA Sequencing System. CD48 mutants were
generated directly in pEF-BOS/srCD48-CD4 by using
the Muta-Gene Phagemid Mutagenesis kit v. 2 (BioRad).
Mutagenic oligonucleotides were used to introduce or
remove a silent restriction site, to facilitate rapid screening of
mutants. All mutations were confirmed initially by restriction
digest and subsequently by dideoxy-sequencing. When
mutations disrupted CD2 binding, the entire V-set
immunoglobulin domain of CD48 was sequenced to exclude
spurious mutations.
Mutant srCD48-CD4 chimeras were expressed in COS-7 cells
(80 cm2 tissue culture flasks) by DEAE transfection using the
method of Seed and Aruffo [65] with 2.5 cg of plasmid DNA.
Following transfection, the cells were grown for 3-5 days in
5 ml of RPMI medium (Gibco) with 10 % fetal calf serum,
glutamine, and antibiotics, after which time the tissue culture
supernatant was harvested, cleared by centrifuging at
10 000 xg for 30 min and stored at 4 °C with added sodium
azide (10 mM) as a preservative..
Expression of CD2 mutants
DNA encoding domain 1 of rat CD2 (CD2dl) was subcloned
into M13 mp18 and mutated using a commercial kit (Sculptor,
Amersham). Mutagenic oligonucleotides were used to intro-
duce a silent restriction site, to facilitate screening for mutants.
Mutations were confirmed by sequencing, and CD2dl was
subcloned into the bacterial expression vector pGEX-2T. The
mutants were expressed as fusion proteins with glutathione S-
transferase (CD2dl-GST) and were expressed and purified as
described previously [37]. All mutants were analyzed by
SDS-PAGE and shown to bind the anti-CD2 monoclonal
antibodies OX34 or OX55 (S.J.D., E.A.D. and P.A.V,
unpublished observations).
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BIAcore experiments
All BlAcore experiments were performed on a BAcore
biosensor (Pharmacia Biosensor AB, Uppsala, Sweden) at
25 C, in the running buffer HBS (150 mM NaCI,
1 mM CaC12, 1 mM MgC12, 10 mM HEPES, pH 7.4), and
0.005 % Surfactant P-20 (Pharmacia). The anti-CD4 mono-
clonal antibody OX68 (IgG2a; M. Puklavec and A.N.B,
unpublished observations) was immobilized by amine coupling
as described previously [44] and was regenerated by injecting
0.1 M glycine/HCl (pH 2.5) for 3 min.
Molecular graphics and modelling
All modelling and molecular graphics production was per-
formed using QUANTA version 4.0 (Molecular Simulations,
Burlington, Massachusetts). The CD48 model shown in Figure
3 was created by homology modelling as implemented in
QUANTA. Briefly, rat CD2 V-set domain coordinates were
copied onto the CD48 sequence on the basis of the alignment
shown in Figure 1. Gaps and extra residues, all of which were
in loop regions (Fig. 1), were modelled by copying fragments
from a library of immunoglobulin superfamily structures in the
Brookhaven protein database, and then regularizing the copied
loops. The structure was then energy-minimized using
CHARMM as implemented in QUANTA. The modelled
CD48 structure is very similar to CD2, with the only signifi-
cant difference being within the loop regions.
To minimize speculation, a more conservative approach was
used to obtain the model of CD48 shown in Figures 5 and 6.
As the core 13-sheets of CD48 are so similar to the CD2 struc-
ture, CD48 was modelled as the rat CD2 C trace with two
CD48 residues, R31 and E44, placed in the positions (E41 and
E29) predicted by the alignment (Fig. 1). The CD48 residue
E44 is equivalent to rat CD2 E41 and is shown unmodified.
The CD48 residue R31 was created by mutating the CD2
residue D29 to R and then selecting a standard arginine
rotamer that minimized contacts with neighbouring residues
on the same 13-sheet.
The head-to-head orientation of the CD2-CD48 complex
(Fig. 5a) is that of the rat CD2CD2 crystal lattice homodimer
with CD48 residues modelled on one of the CD2 C traces.
The three-layer packing orientation (Fig. 5b) was modelled by
superimposition of the core (GFCC'ABED) 13 strands of the
V-set domain of rat CD2 onto the V domains of the NEW
antibody Fab fragment [51]. The rat CD2 V-set domain super-
imposed on VL and VH with 1.0 and 1.4 A root mean square
deviation, respectively. The CD48 residues were then mod-
elled on one of the CD2 Ca traces.
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